KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
The results of KONFIDENT were simultaneously published in The New England Journal of Medicine.
- The results of KONFIDENT were simultaneously published in The New England Journal of Medicine.
- Subgroup analyses showed a consistency of treatment effect in among attacks regardless of attack severity, attack location, use of long-term prophylaxis, or geography.
- There were no patient withdrawals due to any adverse events and no treatment-related serious adverse events (SAEs) were observed.
- Treatment-related adverse event rates were 2.3% for 300 mg sebetralstat, 3.2% for 600 mg sebetralstat, and 4.8% for placebo.